[go: up one dir, main page]

DE60323060D1 - Thiazol- und oxazolderivaten als ppar modulatoren - Google Patents

Thiazol- und oxazolderivaten als ppar modulatoren

Info

Publication number
DE60323060D1
DE60323060D1 DE60323060T DE60323060T DE60323060D1 DE 60323060 D1 DE60323060 D1 DE 60323060D1 DE 60323060 T DE60323060 T DE 60323060T DE 60323060 T DE60323060 T DE 60323060T DE 60323060 D1 DE60323060 D1 DE 60323060D1
Authority
DE
Germany
Prior art keywords
thiazol
oxazole derivatives
ppar modulators
ppar
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60323060T
Other languages
English (en)
Inventor
Xue-Min Cheng
Noe Ouano Erasga
Gary F Filzen
Andrew G Geyer
Chitase Lee
Bharat K Trivedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of DE60323060D1 publication Critical patent/DE60323060D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60323060T 2002-03-07 2003-02-24 Thiazol- und oxazolderivaten als ppar modulatoren Expired - Fee Related DE60323060D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07
PCT/IB2003/000708 WO2003074050A1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity

Publications (1)

Publication Number Publication Date
DE60323060D1 true DE60323060D1 (de) 2008-10-02

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323060T Expired - Fee Related DE60323060D1 (de) 2002-03-07 2003-02-24 Thiazol- und oxazolderivaten als ppar modulatoren

Country Status (29)

Country Link
US (1) US20030207924A1 (de)
EP (1) EP1482935B1 (de)
JP (1) JP2005528348A (de)
KR (1) KR20040091693A (de)
AP (1) AP2004003124A0 (de)
AR (1) AR038881A1 (de)
AT (1) ATE405260T1 (de)
AU (1) AU2003206059A1 (de)
BR (1) BR0308277A (de)
CA (1) CA2478520A1 (de)
CO (1) CO5601012A2 (de)
DE (1) DE60323060D1 (de)
EA (1) EA200400943A1 (de)
EC (1) ECSP045285A (de)
ES (1) ES2310650T3 (de)
HN (1) HN2003000090A (de)
IS (1) IS7377A (de)
MA (1) MA27181A1 (de)
MX (1) MXPA04007564A (de)
NO (1) NO20044242L (de)
OA (1) OA12780A (de)
PA (1) PA8567801A1 (de)
PE (1) PE20030989A1 (de)
PL (1) PL372969A1 (de)
TN (1) TNSN04168A1 (de)
TW (1) TW200305403A (de)
UY (1) UY27695A1 (de)
WO (1) WO2003074050A1 (de)
ZA (1) ZA200406068B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7462629B2 (en) * 2003-05-19 2008-12-09 Irm Llc Immunosuppressant compounds and compositions
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1745003B1 (de) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Neue verbindungen, ihre herstellung und verwendung
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1751120A4 (de) * 2004-05-25 2010-05-05 Metabolex Inc Substituierte triazole als ppar-modulatoren und herstellungsverfahren dafür
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
US20090054493A1 (en) * 2005-02-25 2009-02-26 Heonjoong Kang Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
US7982050B2 (en) * 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
JP5084503B2 (ja) * 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
EP1999098A2 (de) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2139843B1 (de) 2007-04-16 2013-12-25 Amgen, Inc Substituierte biphenyl phenoxy-, thiophenyl- und aminophenylpropansäure als gpr40-modulatoren
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2009078981A2 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
CA2716352C (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
MX2011003917A (es) 2008-10-15 2011-05-31 Amgen Inc Moduladores de grp40 espirociclicos.
WO2011105643A1 (ko) * 2010-02-25 2011-09-01 서울대학교산학협력단 퍼록시솜 증식자 활성화 수용체 리간드 셀레나졸 유도체, 이의 제조방법 및 이들 화합물의 용도
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
AU740444B2 (en) * 1996-08-19 2001-11-01 Japan Tobacco Inc. Propionic acid derivatives and use thereof
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
CN1578659A (zh) * 2001-06-07 2005-02-09 伊莱利利公司 过氧化物酶体增殖剂激活的受体(ppar)的调节剂

Also Published As

Publication number Publication date
ATE405260T1 (de) 2008-09-15
US20030207924A1 (en) 2003-11-06
PE20030989A1 (es) 2003-11-29
PA8567801A1 (es) 2003-11-12
BR0308277A (pt) 2004-12-28
OA12780A (en) 2006-07-07
TNSN04168A1 (fr) 2007-03-12
ZA200406068B (en) 2005-09-06
JP2005528348A (ja) 2005-09-22
ECSP045285A (es) 2004-10-26
PL372969A1 (en) 2005-08-08
AU2003206059A1 (en) 2003-09-16
MXPA04007564A (es) 2004-11-10
EP1482935A1 (de) 2004-12-08
MA27181A1 (fr) 2005-01-03
AP2004003124A0 (en) 2004-09-30
WO2003074050A1 (en) 2003-09-12
EP1482935B1 (de) 2008-08-20
KR20040091693A (ko) 2004-10-28
HN2003000090A (es) 2004-05-05
EA200400943A1 (ru) 2005-02-24
UY27695A1 (es) 2003-10-31
TW200305403A (en) 2003-11-01
NO20044242L (no) 2004-10-06
ES2310650T3 (es) 2009-01-16
CA2478520A1 (en) 2003-09-12
CO5601012A2 (es) 2006-01-31
AR038881A1 (es) 2005-02-02
IS7377A (is) 2004-07-29

Similar Documents

Publication Publication Date Title
DE60323060D1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
NO20044245L (no) Tiazol- og oksazolderivater som modulerer PPAR-aktivitet
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
DE60329601D1 (de) Benzothiazolderivate mit beta-2-adrenorezeptor-agonistenwirkung
CY2015036I2 (el) Νεα παραγωγα οξαζολιδινονης
DE60010333D1 (de) Substituierte oxazole und thiazole derivate als hppar-alpha aktivatore
NO20025978D0 (no) Benzotiazol-derivater
ATE338041T1 (de) Thiazolderivate als phosphodiesterase iv- inhibtoren
NO20043696L (no) Gamma-sekretaseinhibitorer
ATE405562T1 (de) Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
DE60328671D1 (de) Neue aminobenzamidderivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
ATE434436T1 (de) Pestizide (dihalopropenyl) phenylalkyl- substituierte benzoxazol- und benzothiazol- derivate
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
EP1605301A4 (de) Mikrokapsel und anwendung dafür
DE602005015204D1 (de) Oxadiazolonderivate als ppar-delta-agonisten
NO20054674L (no) Benzotiazolderivatforbindelser, preperater og anvendelser
ATE444290T1 (de) Oxazolderivate von tetracyclinen
ATE423771T1 (de) Tetrahydrochinolinderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee